Stocks Health care RMD
NYSE · Health careResmed Inc (RMD)
Resmed Inc reported revenue of $5.7B in fiscal 2026, up 9.9% from a year earlier. Net income was $1.5B, a net margin of 26.9%. Operating cash flow minus capital spending left $1.6B of free cash flow in fiscal 2026. At June 30, 2026 it held $1.5B in cash against $399.4M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on August 13, 2026.
Watch RMD in 60 secondsWhat Resmed Inc does
Resmed Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker RMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $5.7B | $1.5B | $10.43 | $1.6B |
| 2025 | $5.1B | $1.4B | $9.51 | $1.7B |
| 2024 | $4.7B | $1B | $6.92 | $1.3B |
| 2023 | $4.2B | $897.6M | $6.09 | $573.6M |
| 2022 | $3.6B | $779.4M | $5.30 | $216.3M |
| 2021 | $3.2B | $474.5M | $3.24 | $634M |
Full financial statements: income, balance sheet and cash flow
Where RMD ranks in Health care
Dividends
Resmed Inc declared $2.40 per share in fiscal 2026. At the current price that is a yield of 1.08%. It paid out $349.7M in cash dividends, 23% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2026 | $2.40 | $349.7M | 23% |
| 2025 | $2.12 | $310.9M | 22% |
| 2024 | $1.92 | $282.3M | 28% |
| 2023 | $1.76 | $258.3M | 29% |
| 2022 | $1.68 | $245.3M | 31% |
| 2021 | $1.56 | $226.7M | 48% |
Latest SEC filings
What Resmed Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026Other event 8-K
- August 17, 2026
- August 13, 2026Annual report 10-K · period to June 30, 2026Revenue rose 9.9% to $5.7B versus the prior year; diluted EPS $10.43 versus $9.51.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- July 7, 2026
- May 26, 2026
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 11% to $1.4B versus the same quarter last year; diluted EPS $2.74 versus $2.48.
- April 30, 2026
- April 30, 2026
What is RMD worth? A DCF from its reported cash flow
Insider trades
What the people running Resmed Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| September 8, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1.1M |
| September 2, 2026 | Farrell Peter CDirector | Soldpre-planned (10b5-1) | 970 | $227.7K |
| August 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| August 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1M |
| August 5, 2026 | Farrell Peter CDirector | Soldpre-planned (10b5-1) | 8,000 | $1.8M |
| July 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| July 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1.1M |
| June 8, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| June 8, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $968.1K |
| June 1, 2026 | Rider Michael JGlobal General Counsel | Shares withheld for tax | 269 | $51.2K |
| May 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| May 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1M |
| April 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| April 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1.1M |
Who owns RMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 8.21% | April 29, 2026 |
| AustralianSuper Pty Ltd13G, passive | 5.7% | August 7, 2026 |
| Vanguard Portfolio Management13G, passive | 5.41% | April 29, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 707,120 shares in total, about $157.1M at the last price.
| Holder | Shares |
|---|---|
| Farrell Michael J.Chairman and CEO, Director | 466,256 |
| Sandercock BrettChief Financial Officer | 83,495 |
| Farrell Peter CDirector | 51,803 |
| Leong JustinChief Product Officer | 29,028 |
| Taylor Ronald RDirector | 24,771 |
| Gill HarjitDirector | 10,940 |
| Drexler KarenDirector | 10,602 |
| Rider Michael JGlobal General Counsel | 9,488 |
| Tan DesneyDirector | 6,002 |
| Hernandez JohnDirector | 5,118 |
Questions about RMD
What does Resmed Inc do?
Resmed Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker RMD.
Is Resmed Inc profitable?
Yes. In fiscal 2026 it reported net income of $1.5B on revenue of $5.7B, a net margin of 26.9%.
How much revenue does Resmed Inc make?
In fiscal 2026 Resmed Inc reported revenue of $5.7B. That is 9.9% more than a year earlier.
When did Resmed Inc last report?
Its most recent periodic report is the annual report (10-K) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Compare RMD with
Follow RMD
Get an email when Resmed Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow RMD: get an email when it filesWhere the numbers come from
Financial figures are the values Resmed Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.